Immunocore Holdings plc Interest Expense On Lease Liabilities
Immunocore Holdings plc (IMCR) reported Interest Expense On Lease Liabilities of GBP 1.80 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-01.
Discontinued › Expense Statement › Interest Expense
ifrs-full:InterestExpenseOnLeaseLiabilities · last filed 2023-03-01
- Immunocore Holdings plc interest expense on lease liabilities for the quarter ending 2022-12-31 was 480.00K GBP, a 11.37% increase year-over-year.
- Immunocore Holdings plc interest expense on lease liabilities for the quarter ending 2022-09-30 was 461.00K GBP, a 7.71% increase year-over-year.
- Immunocore Holdings plc interest expense on lease liabilities for the quarter ending 2021-12-31 was 431.00K GBP.
- Immunocore Holdings plc interest expense on lease liabilities for the quarter ending 2021-09-30 was 428.00K GBP.
| Period end | Interest Expense On Lease Liabilities 3 month | Interest Expense On Lease Liabilities 6 month | Interest Expense On Lease Liabilities 9 month | Interest Expense On Lease Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | 480.00K GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 941.00K GBP derived: sum of 2 quarters · filed 2023-03-01 | 1.80M GBP 20-F · filed 2023-03-01 | |
| 2022-09-30 | 461.00K GBP 6-K/A · filed 2022-11-18 | 1.32M GBP 6-K/A · filed 2022-11-18 | ||
| 2021-12-31 | 431.00K GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 859.00K GBP derived: sum of 2 quarters · filed 2023-03-01 | 1.73M GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | 428.00K GBP 6-K/A · filed 2022-11-18 | 1.30M GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | 2.40M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | 2.95M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | 0.00 GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |